Outcomes of Children and Adolescents with Acute Myeloid Leukemia and KIT Mutations Treated with Low- or Standard-Dose Chemotherapy Plus Dasatinib on the CALSâ…˘-AML18 Trial
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-211911
Abstract: Introduction: Acute myeloid leukemia (AML) with KIT mutations is associated with poor prognosis. Dasatinib, a tyrosine kinase with KIT inhibitory properties, represents an additional therapeutic approach for this subset of AML. However, its efficacy for… read more here.
Keywords: dasatinib group; kit mutations; dasatinib; group ... See more keywords